AEArmando Estévez-González

Armando Estévez-González

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Armando Estévez-González has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preclinical Memory Profile in Alzheimer Patients with and without Allele APOE-epsilon4

    by Armando Estévez-González, Carmen García-Sánchez, Anunciación Boltes, Pilar Otermín, Montserrat Baiget, Antonio Escartín, Elisabeth del Rio, Alex Gironell, Jaime Kulisevsky

    To investigate the association between APOE-Ε4 allele and memory phenotype in the preclinical stage of Alzheimer’s disease (AD). We compared an extensive preclinical memory profile at the baseline evaluation of 2 AD genotype groups: APOE-Ε4 allele carriers and patients with APOE-Ε3 homozygosity. Baseline memory performance was carried out at least 2 years (interval of 27.7 ± 4 months) before AD diagnosis was established, and analysis included different modalities of working memory (visuoperceptive, visuospatial, digit span and processing speed), of declarative memory (recent, verbal learning, prospective and semantic) and of nondeclarative memory (procedural, incidental and priming). We found no significant differences: memory performance was similar in both genotype groups. The presence of the APOE-Ε4 allele does not seem to be sufficient to cause a distinctive preclinical memory phenotype in AD patients.


  • Semantic Knowledge of Famous People in Mild Cognitive Impairment and Progression to Alzheimer’s Disease

    by Armando Estévez-González, Carmen García-Sánchez, Anunciación Boltes, Pilar Otermín, Berta Pascual-Sedano, Alex Gironell, Jaime Kulisevsky

    Patients with dementia of Alzheimer’s type (DAT) show severe impairment in recognizing famous people. The aim of the current study was to investigate if this well-known memory impairment of famous faces is already present in the preclinical phase of DAT and if the famous faces test can help to differentiate patients with mild cognitive impairment (MCI) who progress to dementia and those who do not. We compared baseline performance in a task of famous face identification in a sample of 116 patients with subjective memory complaints classified in three groups: 17 participants with no evidence of cognitive impairment; 26 patients with MCI who had not developed dementia, and 27 patients with MCI who had developed probable DAT 2 years later. The remaining patients were excluded because they abandoned or did not meet the applied restrictive criteria for DAT, MCI or control. MCI patients who were diagnosed 2 years later with DAT performed significantly worse in the preclinical phase than MCI and control participants (p < 0.004). Patients with MCI but not DAT obtained intermediate results between control subjects and MCI patients who develop Alzheimer’s disease. A neuropsychological task of semantic knowledge of famous people may be useful in the early diagnosis of Alzheimer’s disease.


  • Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging

    by Armando Estévez‐González, Jaime Kulisevsky, Anunciación Boltes, Pilar Otermín, Carmen García‐Sánchez

    Objective: To confirm that performance in verbal learning and memory test (Rey's Auditory Verbal Learning Test‐RAVLT) is a helpful early neuropsychological marker of dementia of Alzheimer's type (DAT).Methods: RAVLT was administered as part of a more extensive neuropsychological battery at baseline evaluation in 116 unselected patients referred by subjective memory complaints (SMC). Patients were followed longitudinally for 2 years (average interval of 27.7±4 months). Seventy patients were included in the study: 27 developed probable DAT; 17 were diagnosed as cognitively normal persons and 26 were diagnosed with Mild Cognitive Impairment (MCI). Remaining patients abandoned or they did not meet the criteria for DAT, MCI or control. Performance on RAVLT at the baseline evaluation was compared between groups.Results: Patients diagnosed two years later with probable DAT showed lower results, more frequently performed a score of zero at the delayed recall test (Trial 6) and had a percentage of forgetting (difference between Trials 5 and 6) higher than 75%. Score at delayed recall test and percentage of forgetting correlated with functional scales such as MMSE, Geriatric Depression Screening, Informant Questionnaire and Blessed's Dementia Rating.Conclusions: RAVLT could help to identify those patients with SMC who would progress to DAT over a few years, and also to differentiate between the preclinical phase of Alzheimer's disease, mild cognitive impairment and normal aging. A score of zero at the delayed recall test or a percentage of forgetting ≥75% in patients with SMC is suggestive of probable DAT in the future. Copyright © 2003 John Wiley & Sons, Ltd.